Centessa Pharmaceuticals (CNTA) Capital Expenditures (2021 - 2025)

Centessa Pharmaceuticals (CNTA) has 5 years of Capital Expenditures data on file, last reported at $11000.0 in Q4 2025.

• Capital Expenditures for Q4 2025 came in at $11000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $279000.0 (up 720.59% YoY), and the FY2025 annual result was $371000.0, up 991.18% from the prior year.
• Capital Expenditures retreated to $11000.0 in Q4 2025 per CNTA's latest filing, from $234000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $652000.0 in Q4 2022 and troughed at $10000.0 in Q2 2023.
• A 5-year average of $118066.7 and a median of $43000.0 in 2023 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures jumped 918.75% in 2022, then slumped 95.71% in 2023.
• A 5-year view of Capital Expenditures shows it stood at $64000.0 in 2021, then jumped by 918.75% to $652000.0 in 2022, then tumbled by 95.71% to $28000.0 in 2023, then increased by 21.43% to $34000.0 in 2024, then sank by 67.65% to $11000.0 in 2025.
• Business Quant data shows CNTA's Capital Expenditures at $11000.0 in Q4 2025, $234000.0 in Q3 2025, and $34000.0 in Q3 2024.